



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#8
doi
11/7/02

In re the application of: Katherine Galvin, *et al*

Serial No.: 09/635,521

Group Art Unit: 1636

Examiner: Loeb, Bronwen

Filed: August 9, 2000

For: *METHODS AND COMPOSITIONS FOR THE
DIAGNOSIS AND TREATMENT OF
CARDIOVASCULAR AND TUMORIGENIC
DISEASE USING 4941*

Attorney Docket No.: MNI-094

RECEIVED
JAN 03 2001
TECH CENTER 1600/2900

Commissioner for Patents
Washington, D.C. 20231

Certificate of First Class Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

November 30, 2001
Date of Signature and of Mail Deposit

By: Maria C. Laccotripe

Maria C. Laccotripe, Ph.D., J.D.

Agent for Applicant

Limited Recognition Under 37 C.F.R. § 10(b)

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

This communication is submitted in response to the Restriction Requirement dated October 31, 2001 (Paper No. 7) which issued in the above-referenced application.

The Examiner has required restriction of the above-identified application to one of the following inventions under 35 U.S.C. §121:

- I. Claims 1-9 drawn to a method of identifying a nucleic acid molecule associated with a cardiovascular or tumorigenic disorder.
- II. Claims 10-12, drawn to a method of identifying a polypeptide associated with a cardiovascular or tumorigenic disorder.
- III. Claims 13-21, drawn to a method of identifying a subject having a cardiovascular or tumorigenic disorder.

- IV. Claims 22-24, drawn to a method of identifying a subject having a cardiovascular or tumorigenic disorder.
- V. Claims 25-30, drawn to a method for identifying a compound capable of treating a cardiovascular or tumorigenic disorder.
- VI. Claims 31-49, drawn to a method for treating a subject having a cardiovascular or tumorigenic disorder.
- VII. Claims 50-53, drawn to a method for identifying a compound capable of modulating an endothelial cell activity.
- VIII. Claims 54-69, drawn to a method for modulating an endothelial cell activity.

Applicants hereby elect the **Group V** Invention (**claims 25-30**) for prosecution, *without traverse*. Applicants reserve the right to traverse the restriction between the non-elected groups in this or a separate application.

CONCLUSION

In view of the foregoing amendments and foregoing remarks, it is respectfully submitted that the application is in condition for allowance. If a telephone conversation with Applicants' Attorney would expedite the prosecution of the above-identified application, the Examiner is urged to call Applicants' Attorney at (617) 227-7400.

Respectfully submitted



Maria C. Laccotripe, Ph.D., J.D.
Limited Recognition Under 37 C.F.R. § 10(b)
Agent for Applicants

LAHIVE & COCKFIELD, LLP
28 State Street
Boston, MA 02109
Telephone: (617) 227-7400
Facsimile: (617) 742-4214

Date: November 30, 2001



RECEIVED
JAN 03 2001
TECH CENTER 1600/2900

**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE
UNITED STATE PATENT AND TRADEMARK OFFICE**

LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)

Maria C. Laccotripe is hereby given limited recognition under 37 CFR §10.9(b) as an employee of Lahive & Cockfield, LLP, to prepare and prosecute patent applications where the patent applicant is the client of Lahive & Cockfield, LLP, and the attorney or agent of record in the applications is a registered practitioner who is a member of the Lahive & Cockfield, LLP. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Maria C. Laccotripe ceases to lawfully reside in the United States, (ii) Maria C. Laccotripe's employment with Lahive & Cockfield, LLP ceases or is terminated, or (iii) Maria C. Laccotripe ceases to remain or reside in the United States on an H-1 visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Expires: September 4, 2002

Harry I. Moatz
Director of Enrollment and Discipline



LAHIVE
&
COCKFIELD
L L P

COUNSELLORS AT LAW
28 STATE STREET
BOSTON, MASSACHUSETTS 02109-1784
TELEPHONE (617) 227-7400
FAX (617) 742-4214
lc@lahive.com

JOHN A. LAHIVE, JR. (1928-1997)
THOMAS V. SMURZYNSKI
RALPH A. LOREN
GIULIO A. DeCONTI, JR.
ANN LAMPORT HAMMITTE
ELIZABETH A. HANLEY
AMY BAKER MANDRAGOURAS
ANTHONY A. LAURENTANO
KEVIN J. CANNING
JANE E. REMILLARD
DeANN FORAN SMITH
PETER C. LAURO
JEANNE M. DIGIORGIO
DEBRA J. MILASINCIC, Ph.D.
DAVID J. RIKKERS
DAVID R. BURNS
JOHN S. CURRAN
SEAN D. DETWEILER

CYNTHIA L. KANIK, Ph.D.
MEGAN E. WILLIAMS, Ph.D.
RICHA NAND
MICHAEL PHILLIPPS *
LISA M. DIROCCO
HATHAWAY P. RUSSELL ***

SENIOR COUNSEL
JAMES E. COCKFIELD

OF COUNSEL
JEREMIAH LYNCH
WILLIAM A. SCOFIELD, JR.

PATENT AGENTS
THEODORE R. WEST
SHAYNE Y. HUFF, Ph.D.
DANIEL B. KO

TECHNICAL SPECIALISTS
MARIA LACCOTRIPE ZACHARAKIS, Ph.D.**
CYNTHIA M. SOROOS
PETER W. DINI, Ph.D.
EUIHOON LEE
JENNIFER K. ROSENFIELD
ALLAN TAMESHTIT, Ph.D.
CATHERINE E. McPHERSON
ERIC F. WAGNER, Ph.D.
SHAHID HASAN, Ph.D.
JACOB G. WEINTRAUB
PETER A. DIMATTIA
JONATHAN M. SPARKS, Ph.D.
CRISTIN E. HOWLEY, Ph.D.
VINCENT P. LOCCISANO
MERIDETH C. ARNOLD

* Admitted in NY only
** Passed the Patent Bar Examination
*** Admitted to Practice

November 30, 2001

Commissioner for Patents
Washington, D.C. 20231

Re: U.S. Patent Application Serial No. 09/635,521
Title: *METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND
TREATMENT OF CARDIOVASCULAR AND TUMORIGENIC
DISEASE USING 4941*
Applicant(s): Katherine Galvin, *et al.*
Filed: August 9, 2000 Our Reference: MNI-094

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Response to Restriction Requirement;
2. Statement of Limited Recognition for Maria C. Laccotripe; and
3. Return mailroom postcard.

Please charge any necessary fees to our Deposit Account No. 12-0080. The undersigned requests any extension of time necessary to respond. A duplicate of this sheet is enclosed.

Certificate of First Class Mailing (37 C.F.R. §1.8(a))

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on:

November 30, 2001

Date

Maria C. Laccotripe, Ph.D., J.D.
Limited Recognition Under 37 CFR §10.9(b)

Respectfully submitted,

Maria C. Laccotripe, Ph.D., J.D.
Limited Recognition Under 37 CFR §10.9(b)
Agent for Applicants
LAHIVE & COCKFIELD, LLP
28 State Street
Boston, MA 02109
(617) 227-7400

RECEIVED
JAN 03 2001
TECH CENTER 1600/2900